Regression of Burkitt's lymphoma in association with measles infection.
about
Immune recruitment and therapeutic synergy: keys to optimizing oncolytic viral therapy?Oncolytic measles viruses encoding interferon beta and the thyroidal sodium iodide symporter gene for mesothelioma virotherapyGoing viral: a review of replication-selective oncolytic adenovirusesOncolytic virotherapy of canine and feline cancerThe Host Cell Receptors for Measles Virus and Their Interaction with the Viral Hemagglutinin (H) ProteinMeasles virus entry through the signaling lymphocyte activation molecule governs efficacy of mantle cell lymphoma radiovirotherapy.Recombinant measles viruses efficiently entering cells through targeted receptorsThe tumor-associated marker, PVRL4 (nectin-4), is the epithelial receptor for morbillivirusesViral oncolysis - can insights from measles be transferred to canine distemper virus?Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer.Tumor cell marker PVRL4 (nectin 4) is an epithelial cell receptor for measles virusPolyploid measles virus with hexameric genome length.Picornavirus infection leading to immunosuppression.The cellular receptor for measles virus--elusive no more.Oncolytic Viruses to Treat Ovarian Cancer Patients - a Review of Results From Clinical TrialsThe Host Microbiome Regulates and Maintains Human Health: A Primer and Perspective for Non-Microbiologists.RNA viruses as virotherapy agents.Enhanced susceptibility of B lymphoma cells to measles virus by Epstein-Barr virus type III latency that upregulates CD150/signaling lymphocytic activation molecule.Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer.Toll-like receptor 3 signaling converts tumor-supporting myeloid cells to tumoricidal effectors.Attenuated oncolytic measles virus strains as cancer therapeuticsOncolytic viral therapies.Oncolytic measles viruses for cancer therapy.Replication-selective oncolytic viruses in the treatment of cancer.Oncolytic virotherapy in veterinary medicine: current status and future prospects for canine patients.Oncolytic measles virus strains as novel anticancer agents.Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview.Strategies in gene therapy for glioblastoma.Oncolytic adenoviral gene therapy in ovarian cancer: why we are not wasting our time.Oncolytic viral therapy of malignant gliomaThe case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon.Glioma virus therapies between bench and bedside.Clinical development directions in oncolytic viral therapy.Oncolytic viruses: do they have a role in anti-cancer therapy?Adenovirus as a new agent for multiple myeloma therapies: Opportunities and restrictions.Progress of oncolytic viruses in sarcomas.Oncolytic virotherapy with modified adenoviruses and novel therapeutic targets.Antitumor Virotherapy by Attenuated Measles Virus (MV).Oncolytic viral therapy: targeting cancer stem cellsReverse genetics of Mononegavirales: How they work, new vaccines, and new cancer therapeutics
P2860
Q24596171-965067FD-0485-4290-B18A-BEC35B3ACEF7Q24605512-1253FC72-5155-430F-B072-F9B193736F5AQ26797520-B6D8C814-2F3F-442B-8C3A-930E9B39E71DQ27008306-6B56A29A-DA9C-412D-AB2C-A26520769395Q28069519-E2B16D32-86CA-4ED7-8588-207E27915454Q30557338-E2FB5ABE-831F-4DAA-AFAB-6EB48EF4175FQ33603475-3DAB97FB-14A1-4221-90B6-B0390F50CFDAQ33820699-D410538C-47E7-4C3E-AC25-0B894B9B2C7EQ33820717-F58E59BE-06A8-425A-BBEA-926693D05CF5Q33932032-746C789B-D535-444E-9081-247EF254ED98Q34013640-80012747-43A9-4806-A7D1-2323BC3828F6Q34087644-DC241162-7E47-409D-8770-C44DA30BC4D1Q34149230-6F05B7C0-6B21-485E-9CF0-B643D5A3F985Q34263646-8065F593-8146-454E-977B-09928B2CDB87Q34432804-8863624D-5FB3-4FE6-B8D1-78880B887EFBQ34553267-97A0C961-BDE0-40B6-9B46-181F3B1743BFQ35043090-31EF666F-C1BB-4767-8C8C-C0E358314F28Q35051487-85011F07-C63E-4D3E-BE7B-0A71A84D8FF9Q35226511-A0223681-81B8-48BC-8A7B-A7D4D9EA086CQ35751039-1B439711-E991-46F6-B022-7D88D894A12DQ35818876-AF3C0A90-0C35-4448-8E57-3C88BBBCE0BAQ35852258-AD7E6E3D-478A-4E4D-B0B8-55A5C53FE936Q35907056-2507910C-9163-4C22-8C5F-8B5136FB83FEQ35912403-D0303918-135B-4E4A-89E2-56D9F27DB2A1Q36099082-B2023B8E-79B0-4E7B-A25A-D01EF710B6E0Q37261017-40B13479-C145-4F2F-A7E6-31AE6CAF6861Q37280354-940BCDCD-20DE-4921-846B-61F61C6E5078Q37420576-C5D7981E-EDE5-45EB-BAF6-D04BD55D8B3BQ37448942-EFDE8D55-151B-4E60-9CFB-97516FF54592Q37533665-505CD1D8-9178-4B7B-940C-AEFC0CFA1FAEQ37561072-F7A022EE-31AB-4A95-8E20-0E7D7C17007AQ37580510-D5805761-91E5-45DF-806F-A4AE856A2D4FQ37857659-142292CD-B751-45A1-A45F-DD7935AF1943Q37926486-70500795-4699-473D-B140-730348F49859Q37977063-E15B79C1-8419-4BF2-9A67-901944E61F69Q37982449-E2E4088F-3B18-4F9B-BB9D-88594F94B424Q38033591-E6F0C679-CC06-41CF-A738-6800AE97A8E1Q38212137-C924E644-74E1-4736-8C02-93313F639EF2Q38212255-519EC9D2-6A87-49B4-9E59-A0361D4E4976Q38363535-FD8BAE91-EB26-4802-AA09-30473D640501
P2860
Regression of Burkitt's lymphoma in association with measles infection.
description
1971 nî lūn-bûn
@nan
1971年の論文
@ja
1971年学术文章
@wuu
1971年学术文章
@zh-cn
1971年学术文章
@zh-hans
1971年学术文章
@zh-my
1971年学术文章
@zh-sg
1971年學術文章
@yue
1971年學術文章
@zh
1971年學術文章
@zh-hant
name
Regression of Burkitt's lymphoma in association with measles infection.
@en
Regression of Burkitt's lymphoma in association with measles infection.
@nl
type
label
Regression of Burkitt's lymphoma in association with measles infection.
@en
Regression of Burkitt's lymphoma in association with measles infection.
@nl
prefLabel
Regression of Burkitt's lymphoma in association with measles infection.
@en
Regression of Burkitt's lymphoma in association with measles infection.
@nl
P1433
P1476
Regression of Burkitt's lymphoma in association with measles infection.
@en
P2093
A Z Bluming
J L Ziegler
P304
P356
10.1016/S0140-6736(71)92086-1
P407
P577
1971-07-01T00:00:00Z